YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids Abstract #406

Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Aim(s): To test the efficacy and safety of YF476 in patients with type 1 GCs.
Materials and methods: Eight patients with CAG and multiple type 1 GCs were entered into an open pilot study of YF476 once daily by mouth for 12 weeks. Patients underwent upper endoscopy and GCs were counted and measured at 0, 6 and 12 weeks after starting YF476. Serum chromogranin A (CgA) was measured at 0, 3, 6, 9 and 12 weeks after starting YF476, and 12 weeks after stopping it.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark

To read results and conclusion, please login ...

Further abstracts you may be interested in

#621 Occurrence of Type 1 Gastric Carcinoid In Patients with Autoimmune Chronic Atrophic Gastritis
Introduction: The actual incidence of type1 gastric carcinoids (GC1) as a long-term complication of chronic autoimmune atrophic gastritis (CAAG) remains to be clarified as studies are few.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr Roberta E Rossi
#802 Metastatic Type 1 Gastric Carcinoid - A Real Threat or Just a Myth?
Introduction: Metastatic GCA1 are extremely rare and there is no data about their natural history, treatment and prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Dr. Simona Glasberg
#1741 Complete Remission of Hepatic Metastasis after Total Gastrectomy for a Gastric Carcinoid Tumor Type 1: A Case Report
Introduction: A 58-year-old woman was referred to our hospital for hepatic lesions and thickening of the walls of the stomach detected by abdominal CT scan. An upper GI endoscopy showed a lesion of the body of the stomach and the histopathologic exam documented a well differentiated NET. 68Ga-DOTATOC PET showed pathologic uptake in the stomach and in the liver (3 lesions). Circulating chromogranin A and gastrin were 596 ng/ml and 2283 pg/ml respectively
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Valeria Smiroldo
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#763 Endoscopic Therapy with Argon Plasma Coagulation for Multiple Type 1 Gastric Carcinoid Tumors
Introduction: Data regarding Type I gastric carcinoids and their evolution in prospective series are scarce, thus treatment and follow-up are not codified.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Rodrigo Castano